ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Cross-sectional seroprevalence study of measles antibodies among children to identify gaps in population immunity, Ireland, 2024.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDGlobal resurgence of measles highlights the need for countries to identify and address immunity gaps. This is challenging given antibody waning and, in Ireland, the absence of robust national vaccine coverage data, population changes due to migration and outdated population-level seroprevalence data from the last national serosurvey (2003).AIMWe aimed to determine the seroprevalence of measles IgG in children aged 3-17 years in Ireland.METHODSConvenience sampling of anonymised residual serum samples from four hospital laboratories across four of six health regions was conducted between 1 February and 19 June 2024. Samples were tested for measles IgG antibodies using a commercial chemiluminescence immunoassay. Seropositivity was adjusted for test sensitivity and specificity and was calculated by sex, age and location.RESULTSIn total 2,509 of 2,924 samples were seropositive and 415 were seronegative indicating measles IgG seroprevalence of 90.3% (95% confidence interval (CI): 89.2-91.4), with no significant difference by sex. Children aged 3-5 years (94.9%; 95% CI: 92.4-96.6) and 6-9 years (94.2%; 95% CI: 91.7-95.9) had significantly higher seropositivity when compared with children aged 10-13 years (89.1%; 95% CI: 86.6-91.3) and 14-17 years (87.6%; 95% CI: 85.5-89.4).CONCLUSIONOur findings suggest close to adequate protection against measles among children 3-9 years but suboptimal (< 95%) protection among children aged 10-17 years. This immunity gap is not reflected in measles vaccine coverage data, highlighting the utility of seroprevalence data to enhance knowledge of clinical protection at population level and to inform vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.